Greenleaf Trust’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.52M Sell
24,165
-1,273
-5% -$102K 0.01% 250
2025
Q4
$2.43M Sell
25,438
-1,157
-4% -$113K 0.02% 171
2025
Q3
$2.6M Sell
26,595
-175
-0.7% -$18.1K 0.02% 160
2025
Q2
$2.88M Sell
26,770
-1,488
-5% -$151K 0.03% 148
2025
Q1
$2.85M Buy
28,258
+1,665
+6% +$168K 0.03% 150
2024
Q4
$2.38M Buy
26,593
+1,291
+5% +$114K 0.02% 173
2024
Q3
$2.12M Sell
25,302
-181
-0.7% -$14.3K 0.02% 189
2024
Q2
$1.96M Buy
25,483
+944
+4% +$69.1K 0.02% 183
2024
Q1
$1.68M Sell
24,539
-195
-0.8% -$12.5K 0.02% 210
2023
Q4
$1.43M Buy
24,734
+2,197
+10% +$117K 0.02% 226
2023
Q3
$1.19M Buy
22,537
+495
+2% +$26K 0.01% 234
2023
Q2
$1.19M Sell
22,042
-1,180
-5% -$61.6K 0.01% 240
2023
Q1
$1.16M Buy
23,222
+1,890
+9% +$89.1K 0.01% 251
2022
Q4
$987K Buy
21,332
+2,261
+12% +$97.9K 0.01% 272
2022
Q3
$739K Buy
19,071
+2,316
+14% +$92.9K 0.01% 292
2022
Q2
$624K Sell
16,755
-1,294
-7% -$52.7K 0.01% 338
2022
Q1
$799K Buy
18,049
+1,770
+11% +$76.7K 0.01% 292
2021
Q4
$692K Buy
16,279
+1,584
+11% +$66.6K 0.01% 332
2021
Q3
$638K Buy
14,695
+1,214
+9% +$53.7K 0.01% 334
2021
Q2
$576K Buy
13,481
+649
+5% +$27.3K 0.01% 361
2021
Q1
$496K Buy
12,832
+3,929
+44% +$149K 0.01% 377
2020
Q4
$320K Sell
8,903
-2,356
-21% -$84.9K ﹤0.01% 438
2020
Q3
$430K Buy
11,259
+2,205
+24% +$85K 0.01% 322
2020
Q2
$318K Buy
9,054
+846
+10% +$30.5K 0.01% 385
2020
Q1
$268K Sell
8,208
-2,547
-24% -$99.5K 0.01% 360
2019
Q4
$486K Sell
10,755
-125
-1% -$5.23K 0.01% 294
2019
Q3
$443K Buy
10,880
+560
+5% +$23.7K 0.01% 308
2019
Q2
$444K Buy
10,320
+502
+5% +$19.3K 0.01% 305
2019
Q1
$377K Buy
9,818
+733
+8% +$28K 0.01% 329
2018
Q4
$321K Buy
9,085
+1,057
+13% +$38.3K 0.01% 350
2018
Q3
$309K Buy
+8,028
New +$280K 0.01% 388
2018
Q1
Sell
-392
Closed -$10K 553
2017
Q4
$10K Sell
392
-53
-12% -$1.46K ﹤0.01% 655
2017
Q3
$13K Buy
+445
New +$12.3K ﹤0.01% 637

Other funds holding BSX

Greenleaf Trust's BSX Position: Q1 2026 in Review

Greenleaf Trust reduced its Boston Scientific (BSX) stake by 5% in Q1 2026, selling an estimated $102K and leaving 24,165 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #250.

Greenleaf Trust first reported a position in BSX in Q3 2017 and has held it in 33 quarters since. The position peaked at $2.88M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Greenleaf Trust held 24,165 shares of Boston Scientific worth $1.52M as of Q1 2026.
  • Greenleaf Trust sold 1,273 Boston Scientific shares in Q1 2026, an estimated $102K.
  • Boston Scientific made up 0.01% of Greenleaf Trust's portfolio in Q1 2026, its #250 holding.
  • Greenleaf Trust first reported a position in Boston Scientific in Q3 2017 and has held it in 33 quarters since.
  • Greenleaf Trust's Boston Scientific position peaked at $2.88M in Q2 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Greenleaf Trust's 13F filing for Q1 2026, filed 27 Apr 2026.